|Articles|June 20, 2001

Glaxo Recieves FDA Approval on Complete Vaccine Delivery System

PHILADELPHIA, Pa-A combined hepatitis A and B pediatric vaccine within a new safety needle system will soon be on the market. The Food and Drug Administration (FDA) has approved the GlaxoSmithKline Safety Tip-Lok prefilled Tip-Lok syringes, packaged with BD SafetyGlide needles for pediatric does of Havrix (hepatitis A vaccine, inactivated) and Engerix-B (hepatitis B vaccine, recombinant).

The system is the first pediatric vaccine available with the new safety needle system and the only vaccines available with the all-in-one delivery system. This meets the Occupational Safety and Health Administration's (OSHA) newly revised bloodborne pathogens standard.

The system works by using a BS SafetyGlide needle that shields the needle tip after activation, therefore helping prevent needlestick accidents. The Centers for Disease Control and Prevention (CDC) has estimated that safety devices may prevent 88% of needlestick injuries in the future.

For more information about the system or the vaccines, visit www.glaxosmithkline.com.


Related to this article

Infection preventionists in full PPE with children in DRC.  (Image credit: author with AI)
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.